Rocconi Rodney P, Stanbery Laura, Madeira da Silva Luciana, Barrington Robert A, Aaron Phylicia, Manning Luisa, Horvath Staci, Wallraven Gladice, Bognar Ernest, Walter Adam, Nemunaitis John
Mitchell Cancer Institute, Division of Gynecologic Oncology, University of South Alabama, Mobile, AL 36604, USA.
Gradalis, Inc., 2545 Golden Bear Drive, Suite 110, Carrollton, TX 75006, USA.
Vaccines (Basel). 2021 Aug 12;9(8):894. doi: 10.3390/vaccines9080894.
To determine the relationship between gene expression profile (GEP) and overall survival (OS) by NanoString following treatment with Vigil.
Recurrent ovarian cancer patients ( = 21) enrolled in prior clinical trials.
GEP stratified by TIS vs. TIS demonstrated OS benefit (NR vs. 5.8 months HR 0.23; = 0.0379), and in particular, MHC-II elevated baseline expression was correlated with OS advantage ( = 0.038). Moreover, 1-year OS was 75% in TIS patients vs. 25% in TIS ( = 0.03795). OS was also correlated with positive γ-IFN ELISPOT response, 36.8 vs. 23.0 months (HR 0.19, = 0.0098).
Vigil demonstrates OS benefit in correlation with TIS score, elevated MHC-II expression and positive γ-IFN ELISPOT in recurrent ovarian cancer patients.
通过NanoString技术确定使用Vigil治疗后基因表达谱（GEP）与总生存期（OS）之间的关系。
纳入先前临床试验中的复发性卵巢癌患者（n = 21）。
TIS与TIS分层的GEP显示出OS获益（未达到与5.8个月相比，风险比[HR]为0.23；P = 0.0379），特别是，MHC-II基线表达升高与OS优势相关（P = 0.038）。此外，TIS患者的1年OS率为75%，而TIS患者为25%（P = 0.03795）。OS也与γ-干扰素酶联免疫斑点试验（ELISPOT）阳性反应相关，分别为36.8个月和23.0个月（HR 0.19，P = 0.0098）。
Vigil在复发性卵巢癌患者中显示出与TIS评分、MHC-II表达升高及γ-干扰素ELISPOT阳性相关的OS获益。
Zotero 插件
